Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics

Hasnain, Mehrul; Fredrickson, Sonja K.; Vieweg, W. Victor R.; Pandurangi, Anand K.

doi:10.1007/s11892-010-0112-8

Cited by 102 publications

(72 citation statements)

References 49 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] The identifying characteristics of metabolic syndrome are weight gain, hypertension, hyperlipidemia, hyperglycemia, glucose intolerance and insulin resistance. 7 Despite the similarity of SGA-induced metabolic syndrome to other forms of prediabetes, the paucity of knowledge about the underlying physiology of the condition has hindered the development of optimal treatment strategies for controlling metabolic dysregulation. Nevertheless, health care providers have recognized the serious nature of SGAinduced metabolic side effects and have sought to ameliorate them through various interventions.…”

Section: Introductionmentioning

confidence: 99%

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Boyda

Procyshyn²,

Tse

et al. 2012

J Psychiatry Neurosci

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Boyda

Procyshyn²,

Tse

et al. 2012

J Psychiatry Neurosci

View full text Add to dashboard Cite

“…Most recently, Hasnain and colleagues recommended monitoring for diabetes with FPG testing in patients at high risk of developing diabetes 1 and 2 months after starting treatment with antipsychotics [Hasnain et al 2010]. The American Figure 1.…”

Section: Discussionmentioning

confidence: 99%

Physical complications in early clozapine treatment: a case report and implications for safe monitoring

Patel

Allin²

2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Treatment with the antipsychotic clozapine is often complicated by its wide-ranging and sometimes serious adverse effect profile. A link between clozapine therapy and diabetes is well established, although the onset and severity of glucose metabolism abnormalities is variable. Recent literature also suggests there may be an association between clozapine therapy and pneumonia. We review the relevant background literature and present a case of a patient with pre-existing type 2 diabetes mellitus and chronic obstructive pulmonary disease who presented with a diabetic emergency after a relatively short period of treatment with clozapine. He went on to develop pneumonia from which he died. We discuss the implications this case, and others alike, have for early routine physical health monitoring of this patient group.

show abstract

“…Moreover, these adverse effects are all risk factors for cardiovascular diseases and along with lifestyle changes and genetic components contribute to the decreased lifespan of patients with schizophrenia. 4 Hence, the aim of the present study was to investigate long-term efficacy as well as the tolerability profile inclusive of metabolic adverse events of iloperidone.…”

Section: Ijaimsmentioning

confidence: 99%

Long-term Effectiveness and Tolerability Profile of Iloperidone in Patients of Psychosis

Kuchhal¹,

Singh²,

Singh³

et al. 2017

International Journal of Advanced and Integrated Medical Sciences

View full text Add to dashboard Cite

Aim:To evaluate the long-term efficacy, tolerability, and safety profile of iloperidone. Materials and methods:A 12 month, prospective, interventional, open label, flexible dose study was conducted on 50 drug naïve, first-episode patients aged 18 to 65 years, fulfilling the International Classification of Diseases-10 criteria for psychosis, for assessing long-term efficacy and adverse events, including biochemical parameters of iloperidone. Detailed clinical examination was carried out. Sociodemographic data and baseline parameters were recorded.Results: Two patients dropped out during the course of therapy. M/F ratio was 1.77:1. Mean age of patients was 28.76 ± 10.28 [mean ± standard deviation (SD)] years. Rural/urban ratio was 2.84:1.25. Patients were illiterate, 18 belonged to low socioeconomic class. It was observed that iloperidone was fairly efficacious not only in preventing relapse or aggravation of symptoms but also well restored the patient to almost near-normal till the end point. After 3 months, 20/48 (41.66%) patients showed significant weight gain that was evident. Mean total weight gain from baseline to end point was 2.89 kg and was statistically significant. There was significant rise in body mass index (BMI) but no patient crossed the upper normal limit. Iloperidone did not cause significant rise (p < 0.6955) in fasting blood sugar (FBS), and no significant alterations in total cholesterol (TC), triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol were recorded. Dizziness was one of the earliest adverse events appearing within 2 to 3 days; others were insomnia, weight gain, increased appetite, anxiety, headache, sedation, etc. Conclusion:On long-term basis, iloperidone is fairly efficacious and has favorable tolerability profile with modest weight gain and practically no alteration in FBS, and lipid profile as well as absence of extrapyramidal side effects.

show abstract

Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics

Cited by 102 publications

References 49 publications

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

Physical complications in early clozapine treatment: a case report and implications for safe monitoring

Long-term Effectiveness and Tolerability Profile of Iloperidone in Patients of Psychosis

Contact Info

Product

Resources

About